Srikanth Neelakantham
- Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjectsBy Veit J. Erpenbeck, Eva Vets, Lien Gheyle, Wande Osuntokun, Michael Larbig, Srikanth Neelakantham, Gerald Dubois and Sheryl PerryVeit J. Erpenbeck1Primary Care, Novartis Pharma AG, Basel, SwitzerlandEva Vets2Life Sciences, SGS-Life Sciences, Antwerp, BelgiumLien Gheyle2Life Sciences, SGS-Life Sciences, Antwerp, BelgiumWande Osuntokun4Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, United KingdomMichael Larbig1Primary Care, Novartis Pharma AG, Basel, SwitzerlandSrikanth Neelakantham3Integrated Information Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, IndiaGerald Dubois4Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, United KingdomSheryl Perry4Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.